Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

ign, scope, enrollment and other aspects of current and planned clinical trials and other studies of Arena's or its collaborators' product candidates and compounds; the tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; the advancement of Arena's R&D efforts; the advancement and content of Arena's pipeline; Arena's collaborations, including expected activities thereunder; expectations relating to the agreements and Arena's relationship with Siegfried; lorcaserin's development, FDA submission and commercialization; financial guidance and assumptions, including relating to partnering and its series B preferred stock; and other statements about Arena's vision, outlook, strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclos
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... Yushan Yan, Distinguished Professor of Engineering at the ... nanomaterials to solve problems in energy engineering, environmental ... focused on zeolites, porous rock with a well-defined, ... size is so precisely decided that zeolites can ... fraction of an angstrom (one-tenth of a nanometer), ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... 2011 Everyday Health, Inc., a leading provider of online ... property has established a partnership with the American College of ... major cardiology meetings, and will become the leader in targeted ... in place at the ACC,s 60th Annual Scientific Session & ...
... Millions of U.S. families face health and safety hazards ... of their homes.  These problems are particularly common among ... the disabled and low-income families.   To ... and Urban Development (HUD), the U.S. Centers for Disease ...
... 2011 Delta Point, Inc., a consulting firm that ... has named Ed Weimer as Executive Account Director. Weimer ... ability to highly motivate, develop and inspire his teams ... to contribute to the organization,s goals. Delta ...
Cached Biology Technology:MedPage Today Signs Exclusive Content & Advertising Deal with the American College of Cardiology for Coverage of More Than 20 Major Cardiology Meetings 2MedPage Today Signs Exclusive Content & Advertising Deal with the American College of Cardiology for Coverage of More Than 20 Major Cardiology Meetings 3Unhealthy Homes Pose Real Danger to Millions of Families 2Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2
(Date:7/24/2014)... sticky research out of York University shows a surprisingly ... toxic grass fungus: moose saliva (yes moose saliva). ... "Ungulate saliva inhibits a grassendophyte mutualism" shows that moose ... (which hosts a fungus called epichlo festucae that produces ... less toxicity. , "Plants have evolved defense mechanisms to ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... this week for an all-day public forum on a ... (EPA) to dredge toxic sediment from an eight-mile stretch ... called the plan, which proposes removing 4.3 million cubic ... riverbed, one of the largest cleanups in the agency,s ... off-site. , "We need to ensure the future well-being ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... genome or the egg genome? Researchers have answered a ... the thousands of long stretches of repeated DNA in the ... The answers, published online by Nature Genetics on ... duplications in the human genome that are partly responsible for ...
... Ph.D., distinguished professor of human genetics and biology at ... and a Howard Hughes Medical Institute investigator, has won ... The announcement was made this morning by the Nobel ... prize recognizes Capecchis pioneering development of knockout mice technology, ...
... University of Cincinnati (UC) radiologists have developed a ... that eases diagnosis of venous diseases. Multi-detector ... create three-dimensional images of arteries, the vessels which ... distribute blood throughout the body. Veins, smaller vessels ...
Cached Biology News:Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 3New thoracic imaging approach can pinpoint underlying venous problems 2
... kit was tested on rat tissue extracts (liver, ... ( S. cerevisae ) extract. It was also ... and cell lines. Application: A simple and reliable ... based on the detection of the inorganic phosphate ...
... Oxidative stress is the condition in which ... oxidant stimuli and the various antioxidants. Oxidative ... the pathogenesis of several diseases, including artherosclerosis, ... body possesses several antioxidant systems that are ...
...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: